PODIATRIC PATHOLOGY REPORT IS;RL;MMR; 1 of 1. A Copy was sent to: DR. JANE DOE 456 SAMPLE BLVD NEW YORK, NY DIAGNOSIS
|
|
- Sheila Cole
- 6 years ago
- Views:
Transcription
1 Batch#: Tel#: CUPTH ccession: Obtained: Received: 12:02 pm PTIENT: JCK JONES MIN ST FLUSHING, NY (718) DOB: 01/02/19XX Specimen Final Report Date cct#: 1018 ge: 57 Sex: Male PODITRIC PTHOLOGY REPORT IS;RL;MMR; 1 of 1 Submitted: 1 vial- RT GRET TOE DIGNOSIS: ONYCHOMYCOSIS 07/19/XX Copy was sent to: DR. JNE DOE 456 SMPLE BLVD DIGNOSIS BC SURGERY CENTER PHYSICIN: JOHN SMITH 1234 FIRST VE, Suite: 8 cct # (212) (212) Notes: PS reveals fungal elements Microscopic Description: Sections show fragments of nail plate with hyperkeratosis and fungal hyphae Grossing Information: Received in 10% Formalin is a specimen measuring 10X03X01 mm, color is tan, shape is Irregular, procedure is Snip and submitted in 1 block, 3 pieces. Grossing Comments: Largest piece measured - see above. PS stain performed Clinical Impression: Color Key: Cancer Precancer/Dysplasia Benign Infectious Inflammatory Suspicious Other typical Photomicrograph of John Brown John Brown, M.D. Board Certified Dermatopathologist Olga Falkowski, M.D., Medical Director : (RT GRET TOE) ONYCHOMYCOSIS JCK JONES JCK JONES Submitted: 1 vial- : (RT GRET TOE) ONYCHOMYCOSIS JCK JONES Submitted: 1 vial- JCK JONES Page 1 of 1
2 Patient: JCK S JONES Date Obtained: Date of Birth: 01/02/19XX Doctor: Dr. JOHN SMITH For Site(s): (212) PTIENT FCT SHEET TM NIL FUNGUS / ONYCHOMYCOSIS / MYCOTIC NILS Definition: fungal infection of the fingernail or toenail. CUSE -Nail fungus is caused by the introduction of a fungus around your nail. -It can enter through: - Cuts in your skin - separation of your nail from the skin around and beneath it SYMPTOMS Your nail may: -Thicken -Turn yellowish or brownish in color -Become foul-smelling, with moist debris around the nail -Become painful, often made worse by pressure METHOD OF DIGNOSIS Many clinicians can diagnose nail fungus by careful observation. However, the removal of a small sample from the affected area for analysis at a reputable pathology laboratory was required for absolute confirmation of the diagnosis, as other conditions can mimic it clinically. Your sample was studied by a specialized pathologist at cupath Laboratories, Inc. before being conclusively diagnosed as Onychomycosis. METHODS OF TRETMENT There are a variety of treatments for nail fungi, which include topical creams, oral medications, and surgery. Your doctor will discuss with you which treatment is best in your specific case. COMMENTS Provided as a service by cupath Laboratories in cooperation with your doctor. cupath Laboratories, Inc. "For the absolute highest standard in pathology services."
3 Batch#: Tel#: CUPTH ccession: Obtained: Received: 12:02 pm PTIENT: JCK JONES MIN ST FLUSHING, NY (718) DOB: 01/02/19XX Specimen Final Report Date cct#: 1018 ge: 57 Sex: Male PODITRIC PTHOLOGY REPORT IS;RL;MMR; 1 of 1 Submitted: 1 vial- RT GRET TOE DIGNOSIS: ONYCHOMYCOSIS 07/19/XX Duplicate Report For DR. JNE DOE 456 SMPLE BLVD DIGNOSIS BC SURGERY CENTER PHYSICIN: JOHN SMITH 1234 FIRST VE, Suite: 8 cct # (212) Rte (212) Notes: PS reveals fungal elements Microscopic Description: Sections show fragments of nail plate with hyperkeratosis and fungal hyphae Grossing Information: Received in 10% Formalin is a specimen measuring 10X03X01 mm, color is tan, shape is Irregular, procedure is Snip and submitted in 1 block, 3 pieces. Grossing Comments: Largest piece measured - see above. PS stain performed Clinical Impression: Color Key: Cancer Precancer/Dysplasia Benign Infectious Inflammatory Suspicious Other typical Photomicrograph of John Brown John Brown, M.D. Board Certified Dermatopathologist Olga Falkowski, M.D., Medical Director : (RT GRET TOE) ONYCHOMYCOSIS JCK JONES JCK JONES Submitted: 1 vial- : (RT GRET TOE) ONYCHOMYCOSIS JCK JONES Submitted: 1 vial- JCK JONES DR. JNE DOE 456 SMPLE BLVD Rte 6 Page 1 of 1
4 BC SURGERY CENTER JOHN SMITH, D.P.M First venue New York, NY July 19, 20XX Dr. Jane Doe 456 Sample Blvd New York, NY Re: Jack S. Jones Dear Dr. Doe: I had the pleasure of treating your patient Jack S Jones, a 57 year old male, on July 18, 20XX. The specimen was sent for pathologic interpretation to cupath Laboratories, Inc. The histopathologic interpretation of the specimen from the () RT GRET TOE revealed onychomycosis. PS reveals fungal elements. I would like to personally thank you for your kind referral. If you have any additional questions, please do not hesitate to contact me at Sincerely, JOHN SMITH, D.P.M.
5 MELNOM FISH NLYSIS REPORT IS;RL;MMR; Page 1 of 1 Tel#: CUPTH Source of Tissue: Indications: Date Reported FISH: Skin Biopsy Left Foot; R/O Melanoma 05/16/20XX CCESSION: Obtained: 05/11/20XX Received: 05/12/20XX PRCTICE: BC SURGERY CENTER PHYSICIN: JOHN D. SMITH 1234 FIRST VE, SUITE: 8 ccount # Rte 9 (212) (212) PTIENT: BETSY J. JONES 1234 NYWHERE NYWHERE, NY Phone #: (516) Chart//C#00000 ge: 78 Sex: Female cct: DOB: 06/05/19XX FINL DIGNOSIS: BNORML, 90% OF CELLS EXHIBIT RELTIVE GINS OF RREB1/CEP 6 ND 53.3% OF CELLS EXHIBIT GINS OF CCND1 FISH NLYSIS DT ssay # Probe Region Chromosome or Locus Normal Percentage Normal Reference Range No. of Cells Scored FISH CCND1 (11q13.3) 46.6% validation in progress 60 D6Z1 (6p11.1-q11) 10% validation in progress 60 MYB (6q23.3) 28.3% validation in progress 60 RREB1 (6p24.3-p25) 0% validation in progress 60 ISCN RESULT: nuc ish(rreb1x3~8)[60],(d6z1x3~5)[54/60],(mybx3~5)[43/60],(ccnd1x3~4)[32/60] INTERPRETTION: Interphase fluorescence in situ hybridization (FISH) was completed on the submitted formalin fixed paraffin embedded left foot biopsy using a panel of four locus specific identifier probes for the following loci: CCND1 (11q13), MYB (6q23), RREB1 (6p25) (Empire Genomics, Buffalo NY), and D6Z1 (CEP 6) (bbott Molecular, Des Plains IL). FISH results were as follows: 54/60 cells (90%) were identified to have relative gains of both the RREB1 and CEP 6 loci. This finding satisfies the abnormal criteria of >55% of the cells having relative gains of these loci (Morey et al. Pathology 2009, pp ). Relative gains of RREB1/CEP6 have been observed in patients with melanocytic tumors (Morey et al. Pathology 2009, pp ). In addition, there were 32/60 cells (53.3%) identified to have 3~4 copies of the CCND1 locus. Gains of the CCND1 locus in >38% of the tissue have been observed in patients with melanoma (Gerami et al. m J Surg Path 2009 pp ). MYB appeared to be present in normal copy number relative to the centromere of chromosome 6. These are BNORML results. These four loci have been identified to have variations in copy number, and can be associated with malignant melanoma (Morey et al. Pathology 2009, pp ). In this case, two of the established abnormal criteria have been satisfied for deeming the case abnormal. These findings should be interpreted in association with other clinical and laboratory findings. Process and limitations of use: 1. The malignant melanoma FISH assay is not an FD-approved FISH test designed to aid in the detection of chromosomal abnormalities related to the development of malignant melanoma. This FISH assay is intended for use as an adjunct to traditional diagnostic procedures and should not be used as the sole basis for the diagnosis of new cancers or for the surveillance of tumor recurrence. 2. positive result by the malignant melanoma FISH assay requires analysis of a minimum of 30 interphase cells that fit the criteria of being morphologically abnormal under a counterstain and that these cells show gains of CCND1 in >38%, or gains of RREB1 in >29%, or relative gains of RREB1/CEP6 in >55%, or relative loss of MYB/CEP6 in >40% of the interphase cells examined. 3. This FISH test was developed and its performance determined by the cupath Cytogenetics Laboratory. lthough it has not been cleared or approved by the U.S. Food and Drug dministration, the FD has determined that such clearance or approval is not necessary. Pursuant to the requirements of CLI '88, however, this laboratory has established and verified the test's accuracy and precision, therefore, this test is used for clinical purposes. 4. The Spitz Nevus FISH assay is not an FD-approved FISH test designed to aid in the detection of chromosomal abnormalities related to the development of Spitz Nevi. This FISH assay is intended for use as an adjunct to traditional diagnostic procedures and should not be used as the sole basis for diagnosis. 5. positive result for the Spitz Nevus FISH assay requires 30% of the tissue to exhibit greater than three-fold the normal diploid copy number for the HRS locus. Increases in HRS locus have been observed in specimens that were diagnosed as Spitz nevus. Electronically signed by: John Brown, M.D. Olga Falkowski, M.D., Medical Director
ORAL MAXILLOFACIAL PATHOLOGY REPORT RL;MMR; 1 of 1. A Copy was sent to: DR. JANE O. DOE 456 SAMPLE BLVD DIAGNOSIS
Batch#: 21838 ccession: Obtained: 04/07/20XX Received: 04/07/20XX 12548 MIN ST FLUSHING, NY 11365 (718) 555-2541 DOB: 01/02/19XX 8:34 pm PTIENT: JCK JONES ORL MXILLOFCIL PTHOLOGY REPORT RL;MMR; 1 of 1
More informationGASTROENTEROLOGY PATHOLOGY REPORT IS;RL;MMR; STPL 1 of 2 11/29/XX 12/01/XX. A Copy was sent to: DR. JANE G. DOE 456 SAMPLE BLVD. NEW YORK, NY 10011
atch#: 11893 Tel#: 1-888-CUPTH ccession: Obtained: 11/28/20XX Received: 11/28/20XX 12:00 am PTIENT: 12548 MIN ST FLUSHING,NY 11365 (718) 365-2541 DO: 01/02/19XX GSTROENTEROLOGY PTHOLOGY REPORT IS;RL;MMR;
More informationGASTROENTEROLOGY PATHOLOGY REPORT IS;RL;MMR; STPL 1 of 1 11/29/XX 12/01/XX. A Copy was sent to: DR. JANE G. DOE 456 SAMPLE BLVD. NEW YORK, NY 10011
atch#: 11893 28 South Terminal Drive Plainview, NY 11803 Tel#: 1-888-CUPTH Fax#: 1-516-326-3452 www.acupath.com ccession: Obtained: 11/28/20XX Received: 11/28/20XX 12:00 am PTIENT: 12548 MIN ST FLUSHING,NY
More informationGYNECOLOGY PATHOLOGY REPORT RL;MMR; STPL 1 of 1 08/29/XX 08/29/XX. A copy was sent to: DR. JANE DOE 456 SAMPLE BLVD NEW YORK, NY DIAGNOSIS
atch#: 12887 Tel#: 1-888-UPTH ccession: Obtained: 08/28/20XX Received: 08/28/20XX 12:05 pm PTIENT: ETSY JONES 1234 NYWHERE NYWHERE, NY 11554 DO: 06/05/19XX Specimen Final Report Date cct#: 1012 ge: 78
More informationENT PATHOLOGY REPORT *RL;MMR; 1 of 1. A Copy was sent to: DR. JANE DOE 456 SAMPLE BLVD NEW YORK, NY DIAGNOSIS
Batch#: 11662 ccession: Obtained: 10/27/20XX Received: 10/28/20XX 1234 anywhere NYWHERE, NY 11554 (516) 123-4567 DOB: 06/05/19XX 8:36 pm PTIENT: Specimen Preliminary Date cct#: 1012 ge: 77 Sex: Female
More informationENT PATHOLOGY REPORT *RL;MMR; 1 of 1. A Copy was sent to: DR. JANE DOE 456 SAMPLE BLVD NEW YORK, NY DIAGNOSIS
Batch#: 11662 Obtained: 10/27/20XX Received: 10/28/20XX 1234 anywhere NYWHERE, NY 11554 (516) 123-4567 DOB: 06/05/19XX 8:36 pm PTIENT: Preliminary Date cct#: 1012 ge: 77 Sex: Female Submitted: 1 vial-
More informationJohn Brown John Brown, M.D.
Batch#: 24724 UROPATHOOGY REPORT IS;R;MMR;STP 1 of 2 Accession: 000000-20XX Obtained: 09/18/20XX Received: 09/18/20XX 6:07 pm PATIENT: 12548 MAIN ST FUSHING, NY 11365 (718) 555-2541 DOB: 01/02/19XX Comments:
More informationHEMATOPATHOLOGY SUMMARY REPORT RL;MMR;
HEMATOPATHOLOGY SUMMARY REPORT RL;MMR; Page 1 of 1 05/15/20XX HP000000-20XX 05/21/20XX (212) 123-457 (51) 32-3455 (51) 123-457 Age: 78 DOB: 0/05/19XX SS#: 45-45-45 Clinical Information: 78 y/o female with
More informationI have no relevant conflicts of interest to disclose. John T. Seykora MD PhD Departments of Dermatology & Pathology and Laboratory Medicine
Molecular Characterization of Stage 1-3 Melanoma: Are we close to accurate prognostication and prediction? I have no relevant conflicts of interest to disclose. John T. Seykora MD PhD Departments of Dermatology
More informationCollected: , PM Sent: , PM Received: , PM Preliminary: , PM. Notification Status: COMPREHENSIVE DIAGNOSIS
PATIENT Name:HIPAA, Compliant DOB: 03-25-1945 (60 yr) ID#: xxx-xx-0000 Sex: M Tel: xxx-xxx-xxxx SPECIMEN Your No:WS05-xxxx Case No:C05-00xxx Req. No:Txxxxx Collected: 06-08-05, PM Sent: 06-09-05, PM Received:
More informationMolecular Aspects of Melanocytic Neoplasia. Iwei Yeh MD, PhD University of California, San Francisco
Molecular Aspects of Melanocytic Neoplasia Iwei Yeh MD, PhD University of California, San Francisco Thanks to: Boris Bastian Timothy McCalmont Philip LeBoit Beth Ruben Jeff North Laura Pincus Thaddeus
More informationMichael T. Tetzlaff MD, PhD
Molecular alterations informing the diagnosis of melanocytic tumors Michael T. Tetzlaff MD, PhD Associate Professor Department of Pathology, Section of Dermatopathology Department of Translational and
More informationCLL Complete SM Report
Reported: 02/01/2012 Σ CGI ID No:5 Client:r Client Address: CLINICAL DATA: Lymphoma No CBC results provided. CLL Complete SM Report FINAL DIAGNOSIS: CD19+ B cell lymphoma, ZAP-70 + (44%), with borderline
More informationUnderstanding the Human Karyotype Colleen Jackson Cook, Ph.D.
Understanding the Human Karyotype Colleen Jackson Cook, Ph.D. SUPPLEMENTAL READING Nussbaum, RL, McInnes, RR, and Willard HF (2007) Thompson and Thompson Genetics in Medicine, 7th edition. Saunders: Philadelphia.
More informationSTUDY. Sensitivity of Fluorescence In Situ Hybridization for Melanoma Diagnosis Using RREB1, MYB, Cep6, and 11q13 Probes in Melanoma Subtypes
STUDY Sensitivity of Fluorescence In Situ Hybridization for Melanoma Diagnosis Using RREB1, MYB, Cep6, and 11q13 Probes in Melanoma Subtypes Pedram Gerami, MD; Mariam Mafee, BS; Teekay Lurtsbarapa, MD;
More informationThe Pathology of Neoplasia Part II
The Pathology of Neoplasia Part II February 2018 PAUL BOGNER, MD A S S O C I A T E P R O F E S S O R O F O N C O L O G Y P A T H O L O G Y A N D D E R M A T O L O G Y Clinical goals of cancer pathology
More informationPage 1 of 3. We suggest the following changes:
Page 1 of 3 Loren E. Clarke, M.D. Myriad Genetic Laboratories, Inc. 320 Wakara Way, Salt Lake City, UT 84108 Phone: 801.883.3470 Email: lclarke@myriad.com Date of Request: June 2017 NCCN Guidelines Panel:
More informationThere is NO single Melanoma Stain. > 6000 Mutations in Melanoma. What else can be done to discriminate atypical nevi from melanoma?
Las Vegas Fall Clinical 2016: The Assessment and Diagnosis of Melanoma Whitney A. High, MD, JD, MEng Associate Professor, Dermatology & Pathology Director of Dermatopathology (Dermatology) University of
More informationVernon K. Sondak. Department of Cutaneous Oncology Moffitt Cancer Center Tampa, Florida
Vernon K. Sondak Department of Cutaneous Oncology Moffitt Cancer Center Tampa, Florida Australasian Melanoma Conference 2016 Sydney, NSW, Australia October 29, 2016 Disclosures Dr. Sondak is a compensated
More informationMelanoma and the genes: Molecular alterations informing the diagnosis of melanocytic tumors
Melanoma and the genes: Molecular alterations informing the diagnosis of melanocytic tumors Michael T. Tetzlaff MD, PhD Associate Professor Department of Pathology, Section of Dermatopathology Department
More informationCopy number and somatic mutations drive tumors
Detection of copy number alterations, ploidy and loss of heterozygosity across the genome in FFPE specimens Utility for diagnosis and treatment with comparison to FISH-based and as a complement to sequencing
More informationCase 26 Male 37. Right jawline 5mm nodule?keloid. The best diagnosis is:
Case 26 Male 37. Right jawline 5mm nodule?keloid. The best diagnosis is: A. Desmoplastic Spitz naevus B. Atypical Spitz Tumour C. Spitzoid melanoma D. Deep penetrating naevus E. Spitz naevus Case 26: M
More informationHER2 FISH pharmdx TM Interpretation Guide - Breast Cancer
P A T H O L O G Y HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer For In Vitro Diagnostic Use FDA approved as an aid in the assessment of patients for whom Herceptin TM (trastuzumab) treatment
More informationHER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer
P A T H O L O G Y HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer FROM CERTAINTY COMES TRUST For in vitro diagnostic use HER2 CISH pharmdx Kit HER2 CISH pharmdx Kit is intended for dual-color
More informationMolecular Methods in the Diagnosis and Prognostication of Melanoma: Pros & Cons
Molecular Methods in the Diagnosis and Prognostication of Melanoma: Pros & Cons Ben J. Friedman, MD Senior Staff Physician Department of Dermatology Department of Pathology and Laboratory Medicine Henry
More informationDiagnosis of melanocytic proliferations remains one of
Update on Fluorescence In Situ Hybridization in Melanoma State of the Art Pedram Gerami, MD; Artur Zembowicz, MD, PhD N Context. Recent advances in understanding the molecular basis of melanoma have resulted
More informationMelanocytic Lesions: Use of Immunohistochemistry and Special Studies Napa Valley 2018
Melanocytic Lesions: Use of Immunohistochemistry and Special Studies Napa Valley 2018 Victor G. Prieto, MD, PhD Professor Depts. of Pathology and Dermatology University of Texas - MD Anderson Cancer Center
More informationApproximately 2% of the United States population
Differentiation of Malignant Melanoma From Benign Nevus Using a Novel Genomic Microarray With Low Specimen Requirements Wells M. Chandler, MD; Leslie R. Rowe, MS; Scott R. Florell, MD; Mona S. Jahromi,
More informationNEW YORK STATE DEPARTMENT OF HEALTH CLINICAL LABORATORY EVALUATION PROGRAM. Crosswalk of Proposed Revisions to Cytogenetics Standards
2014 Standard 2014 Guidance 2016 Standard 2016 Guidance Cytogenetics Standard 1 (CG S1) The laboratory shall request clinical information necessary for proper initiation of test procedures and interpretation
More informationAmerican Society of Cytopathology Core Curriculum in Molecular Biology
American Society of Cytopathology Core Curriculum in Molecular Biology American Society of Cytopathology Core Curriculum in Molecular Biology Chapter 6 Fluorescence in situ Hybridization (FISH) Principles
More informationRole of FISH in Hematological Cancers
Role of FISH in Hematological Cancers Thomas S.K. Wan PhD,FRCPath,FFSc(RCPA) Honorary Professor, Department of Pathology & Clinical Biochemistry, Queen Mary Hospital, University of Hong Kong. e-mail: wantsk@hku.hk
More informationUpdate on Spitzoid and Blue nevus-like melanocytic lesions Emphasis on molecular studies informing diagnosis, prognosis and therapy
Update on Spitzoid and Blue nevus-like melanocytic lesions Emphasis on molecular studies informing diagnosis, prognosis and therapy Michael T. Tetzlaff MD, PhD Associate Professor Department of Pathology,
More informationA PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL
A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL OBJECTIVES Discuss current trends and changing concepts in our understanding of
More informationCanadian College of Medical Geneticists (CCMG) Cytogenetics Examination. May 4, 2010
Canadian College of Medical Geneticists (CCMG) Cytogenetics Examination May 4, 2010 Examination Length = 3 hours Total Marks = 100 (7 questions) Total Pages = 8 (including cover sheet and 2 pages of prints)
More informationMAPK Pathway. CGH Next Generation Sequencing. Molecular Tools in Care of Patients with Pigmented Lesions 7/20/2017
Molecular Tools in Care of Patients with Pigmented Lesions Tammie Ferringer, MD Geisinger Medical Center, Danville, PA tferringer@geisinger.edu DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Tammie Ferringer,
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): In this study the authors analysed 18 deep penetrating nevi for oncogenic genomic changes (single nucleotide variations, insertions/deletions,
More informationDako IT S ABOUT TIME. Interpretation Guide. Agilent Pathology Solutions. ALK, ROS1 and RET IQFISH probes (Dako Omnis) MET IQFISH probe (Dako Omnis)
INTERPRETATION Dako Agilent Pathology Solutions IQFISH Interpretation Guide ALK, ROS1 and RET IQFISH probes (Dako Omnis) MET IQFISH probe (Dako Omnis) IT S ABOUT TIME For In Vitro Diagnostic Use ALK, ROS1,
More informationMelanocytic proliferations in sundamaged
Atypical Spitzoid Tumor: What Does It Mean And How Should It Be Managed? Melanocytic proliferations in sundamaged skin Jane L. Messina, Jane L. Messina MD International Melanoma Pathology Working Group
More informationWAO9 P-32 August 1, 2008 Bank Characterization Report
WAO9 P-32 August 1, 2008 Bank Characterization Report Cell Line description 3 Karyotype.. 4 5 Fluorescent in Situ Hybridization 6 7 Teratoma Assay 8 10 Flow Cytometry.. 11 Post Thaw Recovery 12 2 Cell
More informationManagement of Atypical Pigmented Lesions
Management of Atypical Pigmented Lesions Jennifer A. Stein MD, PhD Associate Director, Pigmented Lesion Section Ronald O. Perelman Department of Dermatology NYU Langone Medical Center July 29, 2017 1-4
More information> 6000 Mutations in Melanoma. Tests That Cay Be Employed. FISH for Additions/Deletions. Comparative Genomic Hybridization
Winter Clinical 2017: The Assessment and Diagnosis of Melanoma Whitney A. High, MD, JD, MEng Associate Professor, Dermatology & Pathology Director of Dermatopathology (Dermatology) University of Colorado
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationSignificance of Chromosome Changes in Hematological Disorders and Solid Tumors
Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Size of Components of Human Genome Size of haploid genome! Estimated genetic constitution! Size of average chromosome
More informationSignificance of Chromosome Changes in Hematological Disorders and Solid Tumors
Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Size of Components of Human Genome Size of haploid genome 3.3 X 10 9 DNA basepairs Estimated genetic constitution 30,000
More informationHow to decipher a pathology report for alopecia
How to decipher a pathology report for alopecia DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Lynne J. Goldberg, MD S063-Hair Disorders Made Easier DISCLOSURES I do not have any relationships with industry
More informationAssociation for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology
Association for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology 9650 Rockville Pike, Bethesda, Maryland 20814 Tel: 301-634-7939 Fax: 301-634-7990 Email:
More informationFAQs for UK Pathology Departments
FAQs for UK Pathology Departments This is an educational piece written for Healthcare Professionals FAQs for UK Pathology Departments If you would like to discuss any of the listed FAQs further, or have
More informationCHROMOSOMAL MICROARRAY (CGH+SNP)
Chromosome imbalances are a significant cause of developmental delay, mental retardation, autism spectrum disorders, dysmorphic features and/or birth defects. The imbalance of genetic material may be due
More informationIntegrating Fluorescence in situ Hybridization and Genomic Array Results into the Diagnostic Workup of Melanoma
Integrating Fluorescence in situ Hybridization and Genomic Array Results into the Diagnostic Workup of Melanoma Association for Molecular Pathology United States and Canadian Academy of Pathology Companion
More informationCorporate Medical Policy
Corporate Medical Policy Gene Expression Profiling for Cutaneous Melanoma File Name: Origination: Last CAP Review: Next CAP Review: Last Review: gene_expression_profiling_for_cutaneous_melanoma 5/2018
More informationUpdate on Genetic Testing for Melanoma
Update on Genetic Testing for Melanoma Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine Hospital of the University of Pennsylvania February 18, 2018 AAD
More informationWhat in the world is Histotechnology? Karen Stiffler, MA, HTL Program Director for Histotechnology
What in the world is Histotechnology? Karen Stiffler, MA, HTL Program Director for Histotechnology The Basics of Histology Histology: the study of body tissues "histo" is from the Greek "histos" meaning
More informationReporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota
Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota Reporting cytogenetics What is it? Terminology Clinical value What details are important Diagnostic Tools for Leukemia
More information6/22/2015. Original Paradigm. Correlating Histology and Molecular Findings in Melanocytic Neoplasms
6 Correlating Histology and Molecular Findings in Melanocytic Neoplasms Pedram Gerami MD, Associate Professor of Dermatology and Pediatrics at Northwestern University Disclosures: I have been a consultant
More informationFISH as an effective diagnostic tool for the management of challenging melanocytic lesions
RESEARCH Open Access FISH as an effective diagnostic tool for the management of challenging melanocytic lesions Mathew W Moore * and Robert Gasparini Abstract Background: The accuracy of melanoma diagnosis
More informationUtility of Adequate Core Biopsy Samples from Ultrasound Biopsies Needed for Today s Breast Pathology
Utility of Adequate Core Biopsy Samples from Ultrasound Biopsies Needed for Today s Breast Pathology Ugur Ozerdem, M.D. 1 Abstract Background: There is a paradigm shift in breast biopsy philosophy. In
More informationWhich melanoma patients benefit from genetic testing?
Which melanoma patients benefit from genetic testing? Michael A. Marchetti, MD Assistant Attending, Dermatology Service Memorial Sloan Kettering Cancer Center American Academy of Dermatology Annual Meeting
More informationPhoebe Rich MD Adjunct Professor OHSU Portland, Oregon
Nail Tips for Diagnosis and Management of Nail Disorders Winter Clinical Dermatology Conference 2017 Hawaii Phoebe Rich MD Adjunct Professor OHSU Portland, Oregon Objectives diagnostic clues for benign
More informationHematopathology Case Study
www.medfusionservices.com Hematopathology Case Study CV3515-14 JUNE Clinical Presentation: Clinical Information: A 42 year old male with history of chronic myelogenous leukemia (CML) presents with an elevated
More informationHistotechnological problems in dermatopathology and their possible consequences
Histotechnological problems in dermatopathology and their possible consequences Zsolt B. Argenyi, M.D. Professor of Pathology & Dermatology Director of Dermatopathology University of Washington, Seattle,
More informationPreface to the Second Edition
Preface to the Second Edition This second edition of Diagnosis of Endometrial Biopsies and Curettings: A Practical Approach follows a number of favorable comments we received about the first edition. As
More informationGene Expression Profiling for Cutaneous Melanoma
Gene Expression Profiling for Cutaneous Melanoma Policy Number: 2.04.146 Last Review: 8/1/2018 Origination: 08/2018 Next Review: 8/1/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationMultispectral Digital Skin Lesion Analysis. Summary
Subject: Multispectral Digital Skin Lesion Analysis Page: 1 of 8 Last Review Status/Date: March 2016 Multispectral Digital Skin Lesion Analysis Summary There is interest in noninvasive devices that will
More informationACMG/CAP Cytogenetics CY
www.cap.org Cytogenetics Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services ACMG/CAP Cytogenetics CY Analyte CY Challenges per Shipment
More informationUW Medicine Neuropathology
Neuropathology in Patient Care Surgical Neuropathology is that subspecialty of pathology that provides diagnoses on biopsies from the brain, spinal cord, skeletal muscle, peripheral nerve, and eye. In
More informationSupplementary Figure 1. Spitzoid Melanoma with PPFIBP1-MET fusion. (a) Histopathology (4x) shows a domed papule with melanocytes extending into the
Supplementary Figure 1. Spitzoid Melanoma with PPFIBP1-MET fusion. (a) Histopathology (4x) shows a domed papule with melanocytes extending into the deep dermis. (b) The melanocytes demonstrate abundant
More informationSURGICAL PATHOLOGY - HISTOLOGY
SURGICAL PATHOLOGY - HISTOLOGY Request Forms The following information is required on the Anatomic Pathology Request form in General Information in all instances: Patient s full name Room number Medical
More informationFISH VALIDATION: HOW I DO IT!
FISH VALIDATION: HOW I DO IT! Theresa C. Brown, PhD, FACMG, CG(ASCP) CM Director, Cytogenetics laboratory Hayward Genetics Center Instructor Tulane University School of Medicine WHERE DO I GET THIS INFORMATION
More informationTracking skin cancers and melanoma at the microscopic level
Tracking skin cancers and melanoma at the microscopic level Rosalie Elenitsas, M.D. Professor of Dermatology Director of Dermatopathology Hospital of the University of Pennsylvania May 12, 2017 Outline
More informationAt Risk Foot Care Protocol Menu
At Risk Foot Care Protocol Menu New Patient /Existing Patient Update Evaluation Questions: Are you Diabetic? If yes, how long have you been Diabetic (when was it diagnosed?) Is your diabetes under control
More informationVACAVILLE DERMATOLOGY
Connecting the Dots on those Spots NANDAN V. KAMATH, M.D. VACAVILLE DERMATOLOGY Sources All of the photos were taken with permission from the Dermnet NZ website - Dermnet New Zealand after communicating
More informationThe Enigmatic Spitz Lesion
The Enigmatic Spitz Lesion The Dawn of Spitz S Spitz Sophie Spitz Melanomas of Childhood ; Am J Pathol 1948 1910-1956 13 children (18 mo - 12 yrs) 12/13 had a benign clinical course Sophie Spitz Born 1910
More informationYour single-source laboratory solution. FISH Probe Library
Your single-source laboratory solution. FISH Probe Library Alphabetical List by Probe with Clinical Indication Probe Clinical Indication 1p36 (TP73)/19q13 (GLTSCR) 1q21 (CKS1B) 5q (CSF1R/RPS14) 7q (MDFIC)
More informationArtur Zembowicz, MD, PhD; Sung-Eun Yang, MD; Antonios Kafanas, MD; Stephen R. Lyle, MD, PhD
Correlation Between Histologic Assessment and Fluorescence In Situ Hybridization Using MelanoSITE in Evaluation of Histologically Ambiguous Melanocytic Lesions Artur Zembowicz, MD, PhD; Sung-Eun Yang,
More informationThree Hours Thirty Minutes
INTERPRETATION HER2 IQFISH pharmdx TM Interpretation Guide Three Hours Thirty Minutes it s about time Breast carcinoma (FFPE) stained with HER2 IQFISH pharmdx Gastric cancer (FFPE) stained with HER2 IQFISH
More informationHSL-Advanced Diagnostics 2018 / 19 Test & Service List
HSL-Advanced Diagnostics 2018 / 19 Test & Service List 2018/19 TEST & SERVICE LIST Haematoxylin & Eosin H&E H&E per slide Routine Immunohistochemistry Immunohistochemical demonstration of an antigen in
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Gene Expression Profiling for Cutaneous Melanoma Page 1 of 28 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Gene Expression Profiling for Cutaneous Melanoma Professional
More informationManagement of pediatric melanocytic lesions
Open Journal of Clinical & Medical Case Reports Management of pediatric melanocytic lesions Volume 3 (2017) Issue 8 ISSN 2379-1039 Jin Kim, BS; Emmanuel Gabriel MD, PhD; Weiguo Liu MD, PhD; Lin Lin MD,
More informationGene Expression Profiling for Cutaneous Melanoma
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationVDx: Unlocking Complex Diagnostics
VDx: Unlocking Complex Diagnostics VDx now offers PARR testing in-house on formalin-fixed tissue Complicated Case? Is this cat s chronic lymphocytic enteritis really chronic IBD or is this early small
More informationCleveland Clinic Laboratories Hematology Diagnostic Services. Trust in us for everything you need in a reference lab.
Cleveland Clinic Laboratories Hematology Diagnostic Services Trust in us for everything you need in a reference lab. Our Mission The Pathology and Laboratory Medicine Institute contributes to excellent
More informationQuality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination
Quality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Outcome DESCRIPTION: Pathology
More informationTHE SPITZ NEVUS OFTEN POSES
OBSERVATION ONLINE FIRST Melanoma Mimic A Case of Multiple Pagetoid Spitz Nevi KaLynne Harris, MD; Scott R. Florell, MD; Jason Papenfuss, MD; Wendy Kohlmann, MS, CGC; Mona Jahromi, BS; Joshua D. Schiffman,
More informationSKIN. 3. How is the skin structured around the finger joints to allow for flexible movement of the fingers?
SKIN Objectives for Exam #1: 1. List various skin structures and describe their functions. 2. Describe skin responses to increases and decreases in body temperature. 3. Provide examples of various skin
More informationDiploma examination. Dermatopathology: First paper. Tuesday 21 March Candidates must answer FOUR questions ONLY. Time allowed: Three hours
Dermatopathology: First paper Tuesday 21 March 2017 1. Discuss the role of fluorescent in-situ hybridization (FISH) and emerging molecular techniques in the diagnosis of cutaneous melanocytic lesions,
More informationWhat Every Pathologist Wants the GI Nurse to Know (and how you can help us help you)
What Every Pathologist Wants the GI Nurse to Know (and how you can help us help you) Jonathan N. Glickman MD PhD Director, GI Pathology, Caris Diagnostics, Newton, MA Associate Professor of Pathology,
More informationTITLE: Identification of Chromosomes Alterations in Primary Breast Cancer Using Premature Chromosome Condensation
AD Award Number: DAMD17-99-1-9237 TITLE: Identification of Chromosomes Alterations in Primary Breast Cancer Using Premature Chromosome Condensation PRINCIPAL INVESTIGATOR: Constance A. Griffin, M.D. CONTRACTING
More informationClassification of Neoplasms
Classification of Neoplasms ICD-10 Chapter 2, Neoplasms Codes C00-D48 Notes at beginning of Chapter 2 Classified by behaviour and site Correct use of Alphabetic index required Main terms Modifiers Table
More informationTypes of Skin Infections
Anatomy of Skin Types of Skin Infections Bacterial Impetigo Folliculitis Acne Fungal /Parasitic Tinea Pedis Tinea Cruris Tinea Versicolor Tinea Corporis Toenail fungus Allergic/Irritation conditions Dermatitis
More informationCytogenetics 101: Clinical Research and Molecular Genetic Technologies
Cytogenetics 101: Clinical Research and Molecular Genetic Technologies Topics for Today s Presentation 1 Classical vs Molecular Cytogenetics 2 What acgh? 3 What is FISH? 4 What is NGS? 5 How can these
More informationGenetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology
Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Outline Germline testing CDKN2A BRCA2 BAP1 Somatic testing Gene expression profiling (GEP) BRAF Germline vs Somatic testing
More informationEducator Navigation Guide
Decoding Breast Cancer Virtual Lab Educator Navigation Guide Decoding Cancer Nav Guide 2 Introduction In this virtual lab, students test tissue samples from different patients with breast cancer in order
More informationCYTOGENETICS Dr. Mary Ann Perle
CYTOGENETICS Dr. Mary Ann Perle I) Mitosis and metaphase chromosomes A) Chromosomes are most fully condensed and clearly distinguishable during mitosis. B) Mitosis (M phase) takes 1 to 2 hrs and is divided
More informationA diagnostic algorithm for atypical spitzoid tumors: guidelines for immunohistochemical and molecular assessment
Modern Pathology (2016), 1 15 2016 USCAP, Inc All rights reserved 0893-3952/16 $32.00 1 A diagnostic algorithm for atypical spitzoid tumors: guidelines for immunohistochemical and molecular assessment
More informationANATOMICAL PATHOLOGY TARIFF
ANATOMICAL PATHOLOGY TARIFF A GUIDE TO UTILISATION. The following guidelines have been agreed by consensus of Anatomical Pathologists who are members of the Anatomical Pathologist s Group, or the National
More informationFor additional information on meeting the criteria for Mohs, see Appendix 2.
Position Statement on Appropriate Uses of Paraffin Sections in Association (Approved by the Board of Directors: August 1, 2011; Revised November 5, 2011; Revised August 9, 2014) According to AMA/CPT, Mohs
More informationApoptosis in cutaneous melanomas
Romanian Journal of Morphology and Embryology 2007, 48(4):343 347 ORIGINAL PAPER Apoptosis in cutaneous melanomas MARIANA COSTACHE 1), OLGA SIMIONESCU 2), MARIA SAJIN 3), ALINA CHEFANI 4), ANA MARIA ENE
More informationBiliary Tract Malignancy-Cyto/FISH
Client Biliary Tract alignancy-cyto/fish Case Number NR-17-2614 A., Right hepatic, brushing (ThinPrep): Cytology: Negative for malignancy. Reactive biliary tract epithelium. Fluorescence in situ hybridization
More informationControversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE
Controversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE Neoadjuvant Chemotherapy Indications: Management of locally advanced invasive breast cancers including inflammatory breast
More information